Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry

Rui Li,Xue Qiao,Qingyan Li,Rong He,Min Ye,Cheng Xiang,Xionghao Lin,Dean Guo

DOI: https://doi.org/10.1016/j.jchromb.2011.07.042

2011-01-01

Abstract:This paper aims to investigate the metabolism and pharmacokinetics of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor. To improve water solubility, nanoparticle formulations were prepared as curcuminoids-loaded solid lipid nanoparticles (curcuminoids-SLNs) and curcumin-loaded solid lipid nanoparticles (curcumin-SLNs). After intragastric administration to tumor-bearing ICR mice, the plasma and tumor samples were analyzed by liquid chromatography with ion trap mass spectrometry. We discovered that curcuminoids were mainly present as glucuronides in plasma, whereas in free form in tumor tissue. A validated LC/MS/MS method was established to determine the three free curcuminoids in tumor homogenate. Samples were separated on a Zorbax SB-C18 column, eluted with acetonitrile–water (containing 0.1% formic acid), and detected by TSQ Quantum triple quadrupole mass spectrometer in selected reaction monitoring mode. The method showed good linearity (r2=0.997–0.999) over wide dynamic ranges (2–6000ng/mL). Variations within- and between-batch never exceeded 11.2% and 13.4%, respectively. The extraction recovery rates ranged from 78.3% to 87.7%. The pharmacokinetics of curcuminoids in mice tumor fit two-compartment model and first order elimination. For curcumin-SLNs group, the dosing of 250mg/kg of curcumin resulted in AUC(0–48h) of 2285ngh/mL and Cmax of 209ng/mL. For curcuminoids-SLNs group, the dosing equivalent to 138mg/kg of curcumin resulted in higher tumor concentrations (AUC=2811ngh/mL, Cmax=285ng/mL). It appeared that co-existing curcuminoids improved the bioavailability of curcumin.